Hyper CVAD Plus Ofatumumab in CD - 20 Positive Acute Lymphoblastic Leukemia (ALL)
Overview[ - collapse ][ - ]
Purpose | The goal of this clinical research study is to learn if ofatumumab combined with standard chemotherapy can help to control ALL. The safety of these drug combinations will also be studied. |
---|---|
Condition | Leukemia |
Intervention | Drug: Cyclophosphamide Drug: Mesna Drug: Doxorubicin Drug: Vincristine Drug: Dexamethasone Drug: Ofatumumab Drug: Methotrexate Drug: Cytarabine |
Phase | Phase 2 |
Sponsor | M.D. Anderson Cancer Center |
Responsible Party | M.D. Anderson Cancer Center |
ClinicalTrials.gov Identifier | NCT01363128 |
First Received | May 27, 2011 |
Last Updated | April 9, 2014 |
Last verified | April 2014 |
Tracking Information[ + expand ][ + ]
First Received Date | May 27, 2011 |
---|---|
Last Updated Date | April 9, 2014 |
Start Date | July 2011 |
Estimated Primary Completion Date | Not Provided |
Current Primary Outcome Measures | Event-Free Survival (EFS) [Time Frame: Assessed beginning Day 14 of Cycle 1, on-going to disease progression (estimated 3+ years)] [Designated as safety issue: No]Event-free survival measured from the start of therapy until failure to respond, relapse or death. |
Current Secondary Outcome Measures | Not Provided |
Descriptive Information[ + expand ][ + ]
Brief Title | Hyper CVAD Plus Ofatumumab in CD - 20 Positive Acute Lymphoblastic Leukemia (ALL) |
---|---|
Official Title | Phase II Study of the Hyper - CVAD Regimen in Combination With Ofatumumab as Frontline Therapy for Patients With CD-20 Positive Acute Lymphoblastic Leukemia |
Brief Summary | The goal of this clinical research study is to learn if ofatumumab combined with standard chemotherapy can help to control ALL. The safety of these drug combinations will also be studied. |
Detailed Description | Study Drug: Ofatumumab is designed to bind to the surface of a type of white blood cells. This may cause cancer cells that come from these white blood cells to die. Central Venous Catheter (CVC): If you are found to be eligible to take part in this study, you will receive a CVC if you do not already have one. A CVC is a sterile flexible tube that will be placed into a large vein while you are under local anesthesia. Your doctor will explain this procedure to you in more detail, and you will be required to sign a separate consent form for this procedure. Study Plan: During Cycles 1-8, you will receive ofatumumab during Cycles 1, 2, 3, and 4. During Cycles 1, 3, 5, and 7, you also will receive cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD). During Cycles 2, 4, 6, and 8, you will also receive methotrexate and cytarabine. After Cycles 1-8, you will receive up to 30 cycles of Maintenance therapy. During Maintenance: - During Cycles 1-5, 8-17, and 20-30, you will receive 6-mercaptopurine, methotrexate, vincristine, and prednisone. - During Cycles 6 and 18 (or Cycles 7 and 19), you will receive cyclophosphamide, vincristine, doxorubicin, dexamethasone, and ofatumumab. - During Cycles 7 and 19 (or Cycles 6 and 18), you will receive methotrexate and pegylated asparaginase. First Phase of Treatment (Cycles 1-8): Every 21 days is a study cycle. You will receive ofatumumab by vein over 4-6 hours on Days 1 and 11 of Cycles 1 and 3 and on Days 1 and 8 of Cycles 2 and 4. During Cycles 1, 3, 5, and 7, you will also receive the following drugs: - On Days 1-3, you will receive cyclophosphamide 2 times a day by vein over 3 hours. - On Days 1-3, you will receive mesna by vein non-stop for the 3 days. The mesna infusion will end about 12 hours after the last dose of cyclophosphamide. - On Day 4, you will receive doxorubicin by vein non-stop for 1 day through the CVC. - On Day 4, you will receive vincristine by vein over 15 minutes. - On Days 1-4 and 11-14, you will receive dexamethasone 1 time a day by vein over 30 minutes or by mouth. During Cycles 2, 4, 6, and 8, you will also receive the following drugs: - On Day 1, you will receive methotrexate by vein over 24 hours. If your doctor thinks it is needed to help reduce the risk of side effects, you may receive leucovorin by vein 4 times a day for 8 doses, beginning 12 hours after the Day 1 methotrexate dose ends. - On Days 2 and 3, you will receive cytarabine by vein 2 times a day over 2 hours. You may receive filgrastim or pegfilgrastim at the end of every cycle to help raise your blood cell counts after you finish chemotherapy. If you receive filgrastim, it will be given by a needle under your skin. If you receive pegfilgrastim, it will be given by a needle under your skin. You may be given other drugs to help prevent side effects. The study staff will tell you about these drugs, how they will be given, and the possible risks. If you are previously untreated for cancer, you will receive the following drugs during Cycles 1-4, or Cycles 1-8 if you have Burkitt's Leukemia/Lymphoma, to help prevent disease in your brain and spinal fluid: - On Day 2, you will receive methotrexate as an injection into the spinal canal (the space surrounding the spinal cord). - On Day 7, you will receive cytarabine as an injection into the spinal canal. If you have mediastinal lymphoblastic lymphoma and bulky mediastinal disease or mediastinal lymphadenopathy (enlarged lymph nodes in the chest area), you may have radiation therapy to the chest area based on the status of the disease. The radiation therapy will be given after you recover from Cycle 8 and before you start Maintenance therapy. Your doctor will explain radiation therapy to you in more detail, and you will be required to sign a separate consent form for this procedure. Maintenance Therapy: During Maintenance Cycles 1-5, 8-17, and 20-30: - You will take 6-mercaptopurine by mouth 3 times daily. - On Day 1, you will receive vincristine by vein over 15 minutes. - You will take methotrexate by mouth weekly. - On Days 1-5, you will take prednisone by mouth. During Maintenance Cycles 6 and 18 (or Cycles 7 and 19), you will receive the same drugs on the same schedule as you did during Cycles 1 and 3. During Maintenance Cycles 7 and 19 (or Cycles 6 and 18): - You will receive methotrexate on Day 1 by vein over 2 hours. - You will receive pegylated asparaginase on Day 2 by vein over 2 hours. If you have Burkitt Leukemia/Lymphoma, you will only receive induction, consolidation and intrathecal chemotherapy (injected into the spinal canal). You will not receive maintenance therapy. Study Visits: You will have a physical exam before each cycle. One (1) time a week during Cycles 1-8, then 1 time a month during Maintenance, blood (about 2-3 teaspoons) will be drawn for routine tests. On Day 14 of Cycle 1, then 1 time a week, you will have a bone marrow aspiration and/or biopsy to check the status of the disease. If the cancer goes into remission (no sign of disease) the bone marrow aspirations/biopsies will then be performed every 4 months. You will have a chest x-ray or PET/CT scan anytime the doctor thinks it is needed. Length of Study: You may receive up to 38 cycles of study drugs. You will no longer be able to take the study drugs if the disease gets worse, if intolerable side effects occur, or if you are unable to follow study directions. Follow-Up: You will be followed for side effects until 30 days after your last dose of study drugs. You will have blood (about 2-3 teaspoons) drawn. Long-Term Follow-Up: The study staff will call you every 3 months for 1 year after you finish receiving the study drugs. During the calls, you will be asked how are you feeling and about any side effects you may have had and any drugs you may have taken. This is an investigational study. Ofatumumab is FDA approved or commercially available for the treatment of chronic lymphocytic leukemia. Its use to treat ALL is investigational. Up to 80 patients will take part in this study. All will be enrolled at MD Anderson. |
Study Type | Interventional |
Study Phase | Phase 2 |
Study Design | Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment |
Condition | Leukemia |
Intervention | Drug: Cyclophosphamide 300 mg/m^2 by vein over 3 hours every 12 hours for 6 doses on Days 1,2,3 (total dose 1800 mg/m2) for courses 1,3,5,7. Other Names:
600 mg/m^2 by vein over continuous infusion daily for 24 hours, starting approximately 1 hour prior to Cyclophosphamide and completing by approximately 12 hours after last dose of Cyclophosphamide for courses 1,3,5,7. Other Names: MesnexDrug: Doxorubicin 50 mg/m^2 by vein over 24 hours on Day 4 via central venous catheter after last dose of Cyclophosphamide given for courses 1,3,5,7. Other Names:
2 mg by vein on Day 4 and Day 11 for courses 1,3,5,7. Drug: Dexamethasone 40 mg by vein or mouth daily on Days 1 - 4 and Days 11 - 14 for courses 1,3,5,7. Other Names: DecadronDrug: Ofatumumab 2000 mg by vein on day 1 and 11 +/- 2 days for courses 1 and 3. (Ofatumumab given at dose of 300 mg on day 1 of cycle 1. Subsequent infusions given at dose of 2000 mg). 2000 mg by vein on Days 1 and 8 for courses 2 and 4. Other Names: ArzerraDrug: Methotrexate 12 mg intrathecally (6 mg via Ommaya reservoir) on Day 2 of courses 1,3,5,7. 200 mg/m^2 by vein over 2 hours followed by 800 mg/m^2 over 22 hours on Day 1 of courses 2,4,6,8. Drug: Cytarabine 100 mg intrathecally on Day 7 for courses 1,3,5,7. 3 g/m^2 by vein over 2 hours every 12 hours for 4 doses on Days 2 and 3 for courses 2,4,6,8. Other Names:
|
Study Arm (s) | Experimental: Hyper-CVAD + Ofatumumab Hyper-CVAD + Ofatumumab (odd courses) Hyper-CVAD + High Dose Methotrexate + Cytarabine + Ofatumumab (even courses) |
Recruitment Information[ + expand ][ + ]
Recruitment Status | Recruiting |
---|---|
Estimated Enrollment | 80 |
Estimated Completion Date | Not Provided |
Estimated Primary Completion Date | August 2016 |
Eligibility Criteria | Inclusion Criteria: 1. Patients of all ages with newly diagnosed, previously untreated CD-20+ ALL, or lymphoblastic lymphoma, Burkitt Leukemia/Lymphoma or having achieved Complete Response (CR) with one course of induction chemotherapy. 2. Failure to one induction course of chemotherapy (these patients will be analyzed separately). 3. Performance status of 0, 1, or 2. 4. Adequate organ function with creatinine less than or equal to 3.0 mg/dL (unless considered tumor related), bilirubin less than or equal to 3.0 mg/dL (unless considered tumor related). 5. Adequate cardiac function defined as no history of arrhythmia, history of MI, or abnormal EKG within 3 months prior to study enrollment. Cardiac function will be assessed by history and physical examination 6. No active or co-existing malignancy (other than ALL or lymphoblastic lymphoma) with life expectancy less than 12 months due to that malignancy. Exclusion Criteria: 1. Pregnant or nursing women. 2. Known to be HIV+ 3. Ph+ ALL 4. Active and uncontrolled disease/infection as judged by the treating physician 5. Unable or unwilling to sign the consent form 6. Subjects who have current active hepatic or biliary disease (with exception of patients with Gilbert's syndrome, asymptomatic gallstones, liver metastases or stable chronic liver disease per investigator assessment) 7. Treatment with any known non - marketed drug substance or experimental therapy within 5 terminal half lives (calculated by multiplying the reported terminal half life by 5) or 4 weeks prior to enrollment, whichever is longer, or currently participating in any other interventional clinical study. 8. History of significant cerebrovascular disease in the past 6 months or ongoing event with active symptoms or sequelae 9. Positive serology for Hepatitis B (HB) defined as a positive test for HBsAg. In addition, if negative for HBsAg but HBcAb positive (regardless of HBsAb status), a HB DNA test will be performed and if positive the subject will be excluded. 10. Positive serology for hepatitis C (HC) defined as a positive test for HCAb, in which case reflexively perform a HC RIBA immunoblot assay on the same sample to confirm the result |
Gender | Both |
Ages | N/A |
Accepts Healthy Volunteers | No |
Contacts | Contact: Elias Jabbour, MD 713-792-4764 |
Location Countries | United States |
Administrative Information[ + expand ][ + ]
NCT Number | NCT01363128 |
---|---|
Other Study ID Numbers | 2010-0708 |
Has Data Monitoring Committee | No |
Information Provided By | M.D. Anderson Cancer Center |
Study Sponsor | M.D. Anderson Cancer Center |
Collaborators | GlaxoSmithKline |
Investigators | Principal Investigator: Elias Jabbour, MD UT MD Anderson Cancer Center |
Verification Date | April 2014 |
Locations[ + expand ][ + ]
UT MD Anderson Cancer Center | Houston, Texas, United States, 77030 Recruiting |
---|